[Pneumocystis carinii and aspergillus pneumonia in immunosuppression in rapidly progressing glomerulonephritis of the anti-glomerular basement membrane type].
Späth
M
M
Abteilung Innere Medizin IV, Medizinische Universitätiklinik Freiburg.
Schollmeyer
P
P
D000328:Adult; D001228:Aspergillosis / Q000175:diagnosis / Q000276:immunology*; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001485:Basement Membrane / Q000276:immunology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D005921:Glomerulonephritis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007678:Kidney Glomerulus / Q000276:immunology*; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000276:immunology*; D009894:Opportunistic Infections / Q000175:diagnosis / Q000276:immunology*; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis / Q000276:immunology*; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone